These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 35412532)

  • 1. Tanezumab for the treatment of osteoarthritis pain.
    Gondal FR; Bilal J; Kent Kwoh C
    Drugs Today (Barc); 2022 Apr; 58(4):187-200. PubMed ID: 35412532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tanezumab in the treatment of chronic musculoskeletal conditions.
    Jayabalan P; Schnitzer TJ
    Expert Opin Biol Ther; 2017 Feb; 17(2):245-254. PubMed ID: 27936977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of tanezumab following intravenous or subcutaneous administration to patients with osteoarthritis or chronic low back pain.
    Shoji S; Suzuki A; Gaitonde P; Cai CH; Marshall S
    Br J Clin Pharmacol; 2022 Jul; 88(7):3321-3334. PubMed ID: 35112378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
    Balanescu AR; Feist E; Wolfram G; Davignon I; Smith MD; Brown MT; West CR
    Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee.
    Spierings ELH; Fidelholtz J; Wolfram G; Smith MD; Brown MT; West CR
    Pain; 2013 Sep; 154(9):1603-1612. PubMed ID: 23707270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial.
    Brown MT; Murphy FT; Radin DM; Davignon I; Smith MD; West CR
    J Pain; 2012 Aug; 13(8):790-8. PubMed ID: 22784777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain.
    Cattaneo A
    Curr Opin Mol Ther; 2010 Feb; 12(1):94-106. PubMed ID: 20140821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Anti-Nerve Growth Factor Monoclonal Antibodies in the Control of Chronic Cancer and Non-Cancer Pain.
    Bimonte S; Cascella M; Forte CA; Esposito G; Cuomo A
    J Pain Res; 2021; 14():1959-1967. PubMed ID: 34234542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis.
    Patel MK; Kaye AD; Urman RD
    J Anaesthesiol Clin Pharmacol; 2018; 34(1):111-116. PubMed ID: 29643634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tanezumab: a selective humanized mAb for chronic lower back pain.
    Webb MP; Helander EM; Menard BL; Urman RD; Kaye AD
    Ther Clin Risk Manag; 2018; 14():361-367. PubMed ID: 29503555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
    Schnitzer TJ; Easton R; Pang S; Levinson DJ; Pixton G; Viktrup L; Davignon I; Brown MT; West CR; Verburg KM
    JAMA; 2019 Jul; 322(1):37-48. PubMed ID: 31265100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tanezumab for the treatment of pain from osteoarthritis of the knee.
    Lane NE; Schnitzer TJ; Birbara CA; Mokhtarani M; Shelton DL; Smith MD; Brown MT
    N Engl J Med; 2010 Oct; 363(16):1521-31. PubMed ID: 20942668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial.
    Hochberg MC; Carrino JA; Schnitzer TJ; Guermazi A; Walsh DA; White A; Nakajo S; Fountaine RJ; Hickman A; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
    Arthritis Rheumatol; 2021 Jul; 73(7):1167-1177. PubMed ID: 33538113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?
    Miller RE; Block JA; Malfait AM
    Curr Opin Rheumatol; 2017 Jan; 29(1):110-118. PubMed ID: 27672741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program.
    Hochberg MC; Tive LA; Abramson SB; Vignon E; Verburg KM; West CR; Smith MD; Hungerford DS
    Arthritis Rheumatol; 2016 Feb; 68(2):382-91. PubMed ID: 26554876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety.
    Schmelz M; Mantyh P; Malfait AM; Farrar J; Yaksh T; Tive L; Viktrup L
    Pain; 2019 Oct; 160(10):2210-2220. PubMed ID: 31145219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment.
    Brown MT; Herrmann DN; Goldstein M; Burr AM; Smith MD; West CR; Verburg KM; Dyck PJ
    J Neurol Sci; 2014 Oct; 345(1-2):139-47. PubMed ID: 25073573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials.
    Chen J; Li J; Li R; Wang H; Yang J; Xu J; Zha Z
    Pain Med; 2017 Feb; 18(2):374-385. PubMed ID: 28034979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee.
    Schnitzer TJ; Marks JA
    Osteoarthritis Cartilage; 2015 Jan; 23 Suppl 1():S8-17. PubMed ID: 25527221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on targets for treating osteoarthritis pain: NGF and TRPV1.
    Obeidat AM; Donner A; Miller RE
    Curr Treatm Opt Rheumatol; 2020 Sep; 6(3):129-145. PubMed ID: 34178580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.